<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Overt hyperthyroidism (low thyroid-stimulating hormone [TSH], elevated free thyroxine [T4] and/or triiodothyronine [T3]) is relatively uncommon during pregnancy, occurring in 0.1 to 0.4 percent of all pregnancies [<a href="#rid1">1,2</a>]. The diagnosis of pregnant women with hyperthyroidism parallels that of nonpregnant individuals but presents some unique problems. The clinical manifestations, diagnosis, and causes of hyperthyroidism during pregnancy are presented here. The treatment of hyperthyroidism during pregnancy and other aspects of thyroid disease during pregnancy are discussed separately. (See  <a class="medical medical_review" href="/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment"</a> and  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy"</a>.)</p><p class="headingAnchor" id="H1972790519"><span class="h1">THYROID PHYSIOLOGY DURING NORMAL PREGNANCY</span><span class="headingEndMark"> — </span>The diagnosis of thyroid disease during pregnancy requires an understanding of the changes in thyroid physiology and thyroid function tests that accompany normal pregnancy. These changes are reviewed briefly below and in more detail separately. (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'Thyroid adaptation during normal pregnancy'</a>.)</p><p>To meet the increased metabolic needs during a normal pregnancy, there are changes in thyroid physiology that are reflected in altered thyroid function tests. These changes include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid hormone-binding globulin (TBG) excess results in high serum total T4 and total T3 concentrations but not high serum free T4 or free T3 concentrations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High serum human chorionic gonadotropin (hCG) concentrations during early pregnancy and even higher concentrations in women with hyperemesis gravidarum or multiple pregnancies may result in transient subclinical or rarely overt hyperthyroidism.</p><p></p><p class="headingAnchor" id="H11"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H995335"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Many of the nonspecific symptoms associated with pregnancy are similar to those associated with hyperthyroidism, including tachycardia, heat intolerance, and increased perspiration. Additional symptoms include anxiety, hand tremor, and weight loss despite a normal or increased appetite. Specific findings such as goiter and ophthalmopathy suggest Graves' hyperthyroidism. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Pregnancy complications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overt hyperthyroidism</strong> (low TSH, with free T4 and/or T3 levels that exceed trimester-specific normal reference ranges or total T4 and T3 that exceed 1.5 times the nonpregnant range) – Pregnancy complicated by poorly controlled overt hyperthyroidism (most often due to Graves' disease) is associated with increased rates of the following [<a href="#rid3">3-7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spontaneous abortion</p><p class="bulletIndent2"><span class="glyph">•</span>Premature labor</p><p class="bulletIndent2"><span class="glyph">•</span>Low birth weight</p><p class="bulletIndent2"><span class="glyph">•</span>Stillbirth</p><p class="bulletIndent2"><span class="glyph">•</span>Preeclampsia</p><p class="bulletIndent2"><span class="glyph">•</span>Heart failure</p><p></p><p class="bulletIndent1">A study of 180 pregnancies complicated by overt hyperthyroidism compared with 360 controls found a higher rate of maternal hypertension and a 1.3- to 1.4-fold increased risk of fetal growth restriction, low birth weight, and preterm birth [<a href="#rid8">8</a>]. The risk of early pregnancy loss also appears to be increased in women with thyroid hormone resistance if the fetus does not carry the mutation, presumably due to the transplacental passage of high levels of thyroid hormone to the fetus. (See  <a class="medical medical_review" href="/d/html/5845.html" rel="external">"Resistance to thyrotropin and thyrotropin-releasing hormone"</a>.)</p><p></p><p class="bulletIndent1">Very rare cases of thyroid storm precipitated by labor, infection, preeclampsia, or cesarean section have been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subclinical hyperthyroidism</strong> (low TSH, with normal free T4 and T3 using trimester-specific normal reference ranges or total T4 and T3 that are less than 1.5 times the nonpregnant range) – In contrast to the findings in women with overt hyperthyroidism, in one report of 433 women with subclinical hyperthyroidism, there was no evidence of adverse pregnancy outcomes [<a href="#rid9">9</a>]. In another report, women with subclinical hyperthyroidism during weeks 4 to 8 of pregnancy had a lower incidence of spontaneous abortion (1.7 versus 7.2 percent in the control group, odds ratio [OR] 0.21, 95% CI 0.05-0.84) and a higher risk of preeclampsia (OR 5.14, 95% CI 1.26-18.1) [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Free T4 in the upper-normal quintile</strong> – A normal free T4 in the upper quintile with a normal TSH has been associated with lower birth weight [<a href="#rid11">11,12</a>] and maternal hypertension [<a href="#rid13">13</a>], but not adverse pregnancy outcomes [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H995354"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Because of the changes in thyroid physiology during normal pregnancy, thyroid function tests may be difficult to interpret. Most pregnant women with significant <strong>overt</strong> hyperthyroidism in the first trimester have a serum TSH below that which is seen in asymptomatic healthy pregnant women (ie, &lt;0.01 mU/L), associated with an elevated free T4 and/or free T3 (or total T4 and/or total T3) measurement that exceeds the normal range during pregnancy [<a href="#rid14">14,15</a>].</p><p>Transient <strong>subclinica</strong>l hyperthyroidism (subnormal TSH with serum total or free T4 and T3 concentrations in the normal range for pregnancy) in the first trimester of pregnancy is considered a normal physiologic finding. True subclinical hyperthyroidism may occur, but it is not typically associated with adverse outcomes during pregnancy [<a href="#rid9">9</a>] and does not require therapy. (See  <a class="medical medical_review" href="/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment"</a>.)</p><p>During normal pregnancy, thyroid function tests should be interpreted using population based, trimester-specific TSH and T4 reference ranges for pregnant women [<a href="#rid15">15</a>]. In several population studies, the lower limit of the reference range for TSH in healthy pregnant women during the first trimester ranged from 0.03 to 0.1 mU/L [<a href="#rid16">16-20</a>]. In one of the largest population-based studies (over 13,000 pregnant women), the reference range (2.5 to 97.5<sup>th</sup> percentile) for TSH in the first trimester was 0.08 to 2.99 mU/L [<a href="#rid16">16,19</a>]. Total T4 and T3 levels during pregnancy are 1.5-fold higher than in nonpregnant women due to thyroid hormone-binding globulin (TBG) excess. Reference ranges for free T4 are assay method specific, and trimester-specific reference ranges should be provided with the assay kits. (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'Trimester-specific reference ranges'</a>.)</p><p class="headingAnchor" id="H994499"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of true hyperthyroidism during pregnancy may be difficult because of the changes in thyroid function that occur during normal pregnancy.</p><p>The diagnosis of hyperthyroidism during pregnancy is based upon clinical manifestations and thyroid function tests. Specific findings on physical examination such as goiter and ophthalmopathy suggest Graves' hyperthyroidism. (See <a class="local">'Graves' disease'</a> below.)</p><p>When there is a clinical suspicion of hyperthyroidism, serum TSH should be measured. If the TSH level is &lt;0.1 mU/L, free or total T4 (or free T4 index) should be obtained. If the free or total T4 is in the normal range for pregnancy, a total T3 should also be measured.</p><p>The diagnosis of overt hyperthyroidism during pregnancy should be based primarily upon a suppressed (&lt;0.1 mU/L) or undetectable (&lt;0.01 mU/L) serum TSH value and a free T4 and/or free T3 (or total T4 and/or total T3) measurement that exceeds the normal range for pregnancy. (See <a class="local">'Laboratory findings'</a> above.)</p><p class="headingAnchor" id="H12186870"><span class="h1">ESTABLISHING THE CAUSE</span><span class="headingEndMark"> — </span>Once the diagnosis of hyperthyroidism is established, the cause of hyperthyroidism should be determined  (<a class="graphic graphic_algorithm graphicRef133239" href="/d/graphic/133239.html" rel="external">algorithm 1</a>). Although hyperthyroidism from any cause can complicate pregnancy, Graves' disease (occurring in 0.1 to 1 percent of all pregnancies) and human chorionic gonadotropin (hCG)-mediated hyperthyroidism due to gestational transient thyrotoxicosis (1 to 3 percent of pregnancies) are the most common causes of hyperthyroidism [<a href="#rid21">21</a>]. Other causes of hyperthyroidism (including silent or subacute thyroiditis, toxic adenoma, toxic multinodular goiter, and factitious thyrotoxicosis) are less common during pregnancy. (See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H4267011769"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>The primary objective is to differentiate Graves' disease from hCG-mediated hyperthyroidism. The two disorders typically can be distinguished based upon clinical findings and laboratory tests. In centers where expertise is available, ultrasound with measurement of thyroidal blood flow can aid in the diagnosis of Graves' disease  (<a class="graphic graphic_algorithm graphicRef133239" href="/d/graphic/133239.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings</strong> – Although the clinical symptoms are similar, the presence of goiter or ophthalmopathy on physical examination favors the diagnosis of Graves' disease. Goiter is not a classical clinical feature of hCG-mediated hyperthyroidism, but it may be present.</p><p></p><p class="bulletIndent1">Graves' disease usually becomes less severe during the later stages of pregnancy due to a reduction in TSH receptor antibody (TRAb) concentrations or, rarely, mediated by a change in the activity of TRAbs from stimulatory to blocking [<a href="#rid22">22,23</a>]. hCG-mediated hyperthyroidism may occur transiently in the first half of gestation and is typically less severe than Graves' disease. (See <a class="local">'Graves' disease'</a> below and <a class="local">'hCG-mediated hyperthyroidism'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation</strong> – In situations where the clinical diagnosis is uncertain, TRAbs, using either a third-generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay or thyrotropin-stimulating immunoglobulin (TSI) assay, should be measured. TRAbs are positive in 96 to 97 percent of patients with Graves' disease, and therefore, the presence of TRAbs confirms the diagnosis of Graves' disease [<a href="#rid15">15,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – In experienced hands, thyroid ultrasound with Doppler flow may be useful to distinguish Graves' disease (high blood flow) from painless or postpartum thyroiditis (low blood flow) [<a href="#rid25">25</a>]. However, its utility in diagnosing hCG-mediated hyperthyroidism is unknown. Thyroid radionuclide imaging is typically performed in nonpregnant patients to distinguish Graves' disease from thyroiditis. However, radionuclide imaging is contraindicated in pregnant women.</p><p></p><p class="headingAnchor" id="H3166170"><span class="h2">Graves' disease</span><span class="headingEndMark"> — </span>Graves' disease is a syndrome that may consist of hyperthyroidism, goiter, thyroid eye disease (orbitopathy), and occasionally a dermopathy referred to as pretibial or localized myxedema. Hyperthyroidism is the most common feature of Graves' disease, affecting nearly all patients, and is caused by TRAbs that activate the receptor, thereby stimulating thyroid hormone synthesis and secretion as well as thyroid growth (causing a diffuse goiter). The presence of TRAbs in serum and thyroid eye disease on clinical examination distinguishes the disorder from other causes of hyperthyroidism. The thyroid gland is usually, but not always, diffusely enlarged. (See  <a class="medical medical_review" href="/d/html/7841.html" rel="external">"Pathogenesis of Graves' disease", section on 'Autoantibodies to the TSH receptor'</a> and  <a class="medical medical_review" href="/d/html/7841.html" rel="external">"Pathogenesis of Graves' disease", section on 'The thyroid gland in Graves' disease'</a>.)</p><p>The importance of measuring maternal serum TRAbs for prediction of fetal and neonatal Graves' disease is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment", section on 'Fetal or neonatal hyperthyroidism'</a> and  <a class="medical medical_review" href="/d/html/5839.html" rel="external">"Evaluation and management of neonatal Graves disease", section on 'Prenatal testing'</a>.)</p><p class="headingAnchor" id="H12187099"><span class="h2">hCG-mediated hyperthyroidism</span><span class="headingEndMark"> — </span>Hyperthyroidism mediated by the effects of hCG include gestational transient thyrotoxicosis (GTT), hyperemesis gravidarum, and trophoblastic hyperthyroidism. Only the last (trophoblastic hyperthyroidism) requires treatment of the hyperthyroidism. (See  <a class="medical medical_review" href="/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment", section on 'Indications for treatment'</a>.)</p><p>During normal pregnancy, serum human chorionic gonadotropin (hCG) concentrations rise soon after fertilization and peak at 10 to 12 weeks gestation, after which time the levels decline. There is considerable homology between the beta-subunits of hCG and TSH. As a result, hCG has weak thyroid-stimulating activity and may cause hyperthyroidism during the period of highest serum hCG concentrations. (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'hCG and thyroid function'</a>.)</p><p class="headingAnchor" id="H12187126"><span class="h3">Gestational transient thyrotoxicosis</span><span class="headingEndMark"> — </span>During the time of peak hCG concentrations (10 to 12 weeks), total serum T4 and T3 concentrations increase. Serum free T4 and T3 concentrations increase slightly, usually within the normal range, and serum TSH concentrations are appropriately reduced. Thus, in some women, the high serum concentration of hCG during early pregnancy can lead to subclinical or mild overt hyperthyroidism characterized by slightly low serum TSH concentrations and high-normal or mildly elevated serum free T4 concentrations [<a href="#rid26">26</a>]. This phenomenon is called GTT. It occurs near the end of the first trimester, and symptoms (if present) and thyroid hyperfunction subside as hCG production falls (typically 14 to 18 weeks gestation). (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'hCG and thyroid function'</a>.)</p><p class="headingAnchor" id="H12187133"><span class="h3">Hyperemesis gravidarum</span><span class="headingEndMark"> — </span>Hyperemesis gravidarum is a syndrome of nausea and vomiting associated with weight loss of 5 percent or more during early pregnancy that occurs in 0.1 to 0.2 percent of pregnancies. Women who develop hyperemesis gravidarum have higher serum hCG and estradiol concentrations than normal pregnant women [<a href="#rid27">27</a>]; in addition, their hCG has more thyroid-stimulating activity [<a href="#rid28">28-30</a>]. Therefore, their serum TSH concentrations are often lower than those in normal pregnant women (60 versus 9 percent had a low serum TSH in one study) [<a href="#rid27">27,29</a>]. A few of these women have high serum free T4 concentrations and, therefore, have overt hyperthyroidism.</p><p>Features that distinguish the transient hyperthyroidism of hyperemesis gravidarum from hyperthyroidism of other causes (which, in a pregnant woman, is most likely due to Graves' disease) are the vomiting, absence of goiter and ophthalmopathy, and absence of the common symptoms and signs of hyperthyroidism (tachycardia greater than 100 beats/minute, hyperdefecation, muscle weakness, tremor). In addition, serum free T4 concentrations are only minimally elevated and serum T3 concentrations may not be elevated in women with hyperemesis gravidarum, whereas both are usually unequivocally elevated in pregnant women with true hyperthyroidism from Graves' disease.</p><p>The thyroid hyperfunction in women with hyperemesis gravidarum usually does <strong>not</strong> require treatment, because it is mild and subsides as hCG production falls (as does the vomiting). Like the thyroid hyperfunction, the vomiting is also proportional to the elevation in serum hCG and estradiol concentrations, and it is thought to be caused by estradiol [<a href="#rid27">27</a>]. If overt hyperthyroidism persists for more than several weeks or beyond the first trimester, it is probably not hCG mediated.</p><p>The clinical presentation, diagnosis, and treatment of hyperemesis gravidarum are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6792.html" rel="external">"Nausea and vomiting of pregnancy: Clinical findings and evaluation"</a> and  <a class="medical medical_review" href="/d/html/6811.html" rel="external">"Nausea and vomiting of pregnancy: Treatment and outcome"</a>.)</p><p class="headingAnchor" id="H12187140"><span class="h3">Trophoblastic hyperthyroidism</span><span class="headingEndMark"> — </span>Hyperthyroidism can also occur with gestational trophoblastic disease. A hydatidiform mole (molar pregnancy) is benign but may give rise to choriocarcinoma. Both are associated with high serum hCG concentrations and abnormal hCG isoforms [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/3230.html" rel="external">"Gestational trophoblastic disease: Pathology"</a>.)</p><p>In the past, approximately 55 to 60 percent of women with trophoblastic disease had clinically evident hyperthyroidism at the time of diagnosis, which could be severe. However, in a review of 196 patients from the United Kingdom treated for gestational trophoblastic disease between 2005 and 2010, biochemical hyperthyroidism was present in 7 percent and clinical hyperthyroidism in only 2 percent [<a href="#rid32">32</a>]. The difference in prevalence is likely related to earlier diagnosis of trophoblastic disease due to ultrasonography and monitoring of serum beta-hCG. (See  <a class="medical medical_review" href="/d/html/3243.html" rel="external">"Hydatidiform mole: Epidemiology, clinical features, and diagnosis"</a>.)</p><p>Many patients with hyperthyroidism caused by trophoblastic disease have a normal thyroid gland and few symptoms of thyroid hormone excess. However, some patients have more typical clinical findings of hyperthyroidism and a diffuse goiter, but ophthalmopathy is not present. Nausea and vomiting may predominate, as in hyperemesis gravidarum.</p><p>The treatment of women with symptomatic moderate to severe hyperthyroidism due to trophoblastic hyperthyroidism is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment", section on 'Indications for treatment'</a>.)</p><p class="headingAnchor" id="H12187147"><span class="h3">Familial gestational hyperthyroidism</span><span class="headingEndMark"> — </span>Recurrent gestational hyperthyroidism has been described in one family due to a mutant thyrotropin receptor that is hypersensitive to physiologic concentrations of hCG [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H606390093"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109107.html" rel="external">"Society guideline links: Hyperthyroidism"</a> and  <a class="medical medical_society_guidelines" href="/d/html/112934.html" rel="external">"Society guideline links: Thyroid disease and pregnancy"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/85876.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2168.html" rel="external">"Patient education: Antithyroid drugs (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Many of the nonspecific symptoms associated with pregnancy are similar to those associated with hyperthyroidism, including tachycardia, heat intolerance, and increased perspiration. Additional symptoms may include anxiety, hand tremor, and weight loss despite a normal or increased appetite. Specific findings such as goiter and ophthalmopathy suggest Graves' hyperthyroidism. (See <a class="local">'Clinical features'</a> above and  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of hyperthyroidism during pregnancy should be based primarily upon a finding of a suppressed (&lt;0.1 mU/L) or undetectable (&lt;0.01) serum thyroid-stimulating hormone (TSH) value and elevated thyroid hormone levels (serum free thyroxine [T4] and/or free triiodothyronine [T3] or total T4 and/or total T3) that exceed the normal range for pregnancy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Establishing the cause</strong> – Once the diagnosis of hyperthyroidism is established, the cause of hyperthyroidism should be determined  (<a class="graphic graphic_algorithm graphicRef133239" href="/d/graphic/133239.html" rel="external">algorithm 1</a>). Although hyperthyroidism from any cause can complicate pregnancy, Graves' (occurring in 0.1 to 1 percent of all pregnancies) and human chorionic gonadotropin (hCG)-mediated hyperthyroidism (1 to 3 percent of pregnancies) are the most common causes of hyperthyroidism. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1">Graves' disease and hCG-mediated hyperthyroidism typically can be distinguished based upon clinical findings and laboratory tests. hCG-mediated hyperthyroidism may occur transiently in the first half of gestation and is typically less severe than Graves' disease. Graves' disease usually becomes less severe during the later stages of pregnancy due to a reduction in TSH receptor antibody (TRAb) concentrations.</p><p></p><p class="bulletIndent1">In situations where the clinical diagnosis is uncertain, we measure TSH receptor antibodies (TRAbs), using a third-generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay or a thyrotropin-stimulating immunoglobulin (TSI) assay. TRAbs are positive in 95 percent of patients with Graves' disease, and therefore, the presence of TRAbs confirms the diagnosis of Graves' disease. If antibodies are negative, thyroid ultrasound with Doppler flow may be useful to distinguish Graves' disease (high blood flow) from painless or postpartum thyroiditis (low blood flow).</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010; 31:702.</a></li><li><a class="nounderline abstract_t">Lo JC, Rivkees SA, Chandra M, et al. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid 2015; 25:698.</a></li><li><a class="nounderline abstract_t">Davis LE, Lucas MJ, Hankins GD, et al. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 1989; 160:63.</a></li><li><a class="nounderline abstract_t">Sheffield JS, Cunningham FG. Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol 2004; 190:211.</a></li><li><a class="nounderline abstract_t">Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, et al. Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. Clin Endocrinol (Oxf) 2001; 54:365.</a></li><li><a class="nounderline abstract_t">Millar LK, Wing DA, Leung AS, et al. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 1994; 84:946.</a></li><li><a class="nounderline abstract_t">Kriplani A, Buckshee K, Bhargava VL, et al. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol 1994; 54:159.</a></li><li><a class="nounderline abstract_t">Luewan S, Chakkabut P, Tongsong T. Outcomes of pregnancy complicated with hyperthyroidism: a cohort study. Arch Gynecol Obstet 2011; 283:243.</a></li><li><a class="nounderline abstract_t">Casey BM, Dashe JS, Wells CE, et al. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 2006; 107:337.</a></li><li><a class="nounderline abstract_t">Zhang Y, Li Y, Shan Z, et al. Association of Overt and Subclinical Hyperthyroidism During Weeks 4-8 with Adverse Pregnancy Outcomes. J Womens Health (Larchmt) 2019; 28:842.</a></li><li><a class="nounderline abstract_t">Medici M, Timmermans S, Visser W, et al. Maternal thyroid hormone parameters during early pregnancy and birth weight: the Generation R Study. J Clin Endocrinol Metab 2013; 98:59.</a></li><li><a class="nounderline abstract_t">Haddow JE, Craig WY, Neveux LM, et al. Implications of High Free Thyroxine (FT4) concentrations in euthyroid pregnancies: the FaSTER trial. J Clin Endocrinol Metab 2014; 99:2038.</a></li><li><a class="nounderline abstract_t">Medici M, Korevaar TI, Schalekamp-Timmermans S, et al. Maternal early-pregnancy thyroid function is associated with subsequent hypertensive disorders of pregnancy: the generation R study. J Clin Endocrinol Metab 2014; 99:E2591.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists.. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. Obstet Gynecol 2002; 100:387.</a></li><li><a class="nounderline abstract_t">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017; 27:315.</a></li><li><a class="nounderline abstract_t">Dashe JS, Casey BM, Wells CE, et al. Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. Obstet Gynecol 2005; 106:753.</a></li><li><a class="nounderline abstract_t">Stricker R, Echenard M, Eberhart R, et al. Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. Eur J Endocrinol 2007; 157:509.</a></li><li><a class="nounderline abstract_t">Gilbert RM, Hadlow NC, Walsh JP, et al. Assessment of thyroid function during pregnancy: first-trimester (weeks 9-13) reference intervals derived from Western Australian women. Med J Aust 2008; 189:250.</a></li><li><a class="nounderline abstract_t">Fitzpatrick DL, Russell MA. Diagnosis and management of thyroid disease in pregnancy. Obstet Gynecol Clin North Am 2010; 37:173.</a></li><li><a class="nounderline abstract_t">Lambert-Messerlian G, McClain M, Haddow JE, et al. First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study. Am J Obstet Gynecol 2008; 199:62.e1.</a></li><li><a class="nounderline abstract_t">Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 2013; 1:238.</a></li><li><a class="nounderline abstract_t">Salvi M, How J. Pregnancy and autoimmune thyroid disease. Endocrinol Metab Clin North Am 1987; 16:431.</a></li><li><a class="nounderline abstract_t">Kung AW, Lau KS, Kohn LD. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy. J Clin Endocrinol Metab 2001; 86:3647.</a></li><li><a class="nounderline abstract_t">Vos XG, Smit N, Endert E, et al. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf) 2008; 69:311.</a></li><li><a class="nounderline abstract_t">Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf) 2007; 67:41.</a></li><li><a class="nounderline abstract_t">Glinoer D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990; 71:276.</a></li><li><a class="nounderline abstract_t">Goodwin TM, Montoro M, Mestman JH, et al. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992; 75:1333.</a></li><li><a class="nounderline abstract_t">Yamazaki K, Sato K, Shizume K, et al. Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles. J Clin Endocrinol Metab 1995; 80:473.</a></li><li><a class="nounderline abstract_t">Kimura M, Amino N, Tamaki H, et al. Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity. Clin Endocrinol (Oxf) 1993; 38:345.</a></li><li><a class="nounderline abstract_t">Hershman JM. Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid 1999; 9:653.</a></li><li><a class="nounderline abstract_t">Yoshimura M, Pekary AE, Pang XP, et al. Thyrotropic activity of basic isoelectric forms of human chorionic gonadotropin extracted from hydatidiform mole tissues. J Clin Endocrinol Metab 1994; 78:862.</a></li><li><a class="nounderline abstract_t">Walkington L, Webster J, Hancock BW, et al. Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease. Br J Cancer 2011; 104:1665.</a></li><li><a class="nounderline abstract_t">Rodien P, Brémont C, Sanson ML, et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med 1998; 339:1823.</a></li><li><a class="nounderline abstract_t">Smits G, Govaerts C, Nubourgh I, et al. Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG. Mol Endocrinol 2002; 16:722.</a></li></ol></div><div id="topicVersionRevision">Topic 7868 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20573783" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thyroid function and human reproductive health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25747892" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912104" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thyrotoxicosis complicating pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14749662" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thyrotoxicosis and heart failure that complicate pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11298089" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7970474" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7523202" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20087627" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Outcomes of pregnancy complicated with hyperthyroidism: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449121" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Subclinical hyperthyroidism and pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30855205" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Association of Overt and Subclinical Hyperthyroidism During Weeks 4-8 with Adverse Pregnancy Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150694" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Maternal thyroid hormone parameters during early pregnancy and birth weight: the Generation R Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24606107" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Implications of High Free Thyroxine (FT4) concentrations in euthyroid pregnancies: the FaSTER trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157540" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Maternal early-pregnancy thyroid function is associated with subsequent hypertensive disorders of pregnancy: the generation R study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12166417" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056690" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16199632" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17893266" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759718" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Assessment of thyroid function during pregnancy: first-trimester (weeks 9-13) reference intervals derived from Western Australian women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20685547" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnosis and management of thyroid disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18585522" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24622372" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hyperthyroidism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3319591" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pregnancy and autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502791" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208575" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437515" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2116437" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Regulation of maternal thyroid during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430095" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7852507" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319364" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10447009" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8157712" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Thyrotropic activity of basic isoelectric forms of human chorionic gonadotropin extracted from hydatidiform mole tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21522146" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854118" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923469" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lysine 183 and glutamic acid 157 of the TSH receptor: two interacting residues with a key role in determining specificity toward TSH and human CG.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
